Table 3 Subgroup analysis according to stroke subtype (cardioembolic stroke vs. non-cardioembolic stroke)
Outcomes | Statin use | No Use | P trend* | ||
|---|---|---|---|---|---|
D1 | D2 | D ≥ 3 | |||
Cardioembolic stroke | |||||
No. of patients | 13 | 39 | 22 | 96 | |
Better primary outcome (mRS, 0-1) | 3 (23.1 %) | 13 (33.3 %) | 7 (31.8 %) | 19 (19.8 %) | 0.19 |
Favorable outcome (mRS, 0-2) | 4 (30.8 %) | 16 (41.0 %) | 9 (40.9 %) | 32 (33.3 %) | 0.63 |
Neurologic improvement | 7 (53.8 %) | 22 (56.4 %) | 14 (63.6 %) | 51 (53.1 %) | 0.75 |
Neurologic deterioration | 3 (23.1 %) | 4 (10.3 %) | 0 (0.0 %) | 26 (27.1 %) | 0.06 |
Ischemic recurrence | 4 (30.8 %) | 4 (10.3 %) | 2 (9.1 %) | 11 (11.5 %) | 0.28 |
Symptomatic hemorrhagic transformation | 0 (0.0 %) | 1 (2.6 %) | 0 (0.0 %) | 10 (10.4 %) | 0.04 |
Non-cardioembolic strokea | |||||
No. of patients | 32 | 31 | 30 | 74 | |
Better primary outcome (mRS, 0-1) | 16 (50.0 %) | 13 (41.9 %) | 11 (36.7 %) | 19 (25.7 %) | 0.01 |
Favorable outcome (mRS, 0-2) | 22 (68.8 %) | 14 (45.2 %) | 20 (66.7 %) | 25 (33.8 %) | 0.003 |
Neurologic improvement | 17 (53.1 %) | 15 (54.8 %) | 24 (80.0 %) | 40 (54.1 %) | 0.86 |
Neurologic deterioration | 4 (12.5 %) | 6 (19.4 %) | 1 (3.3 %) | 19 (25.7 %) | 0.13 |
Ischemic recurrence | 4 (12.5 %) | 7 (22.6 %) | 2 (6.7 %) | 16 (21.6 %) | 0.42 |
Symptomatic hemorrhagic transformation | 1 (3.1 %) | 1 (3.2 %) | 0 (0.0 %) | 7 (9.5 %) | 0.14 |